Targeting the brain: neuroprotection and neurorestoration in ischemic stroke.
Many treatments for acute ischemic stroke are vessel and blood based, but brain-based therapies also hold great promise. Acute neuroprotective therapies block the molecular elaboration of injury in hypoxic environments. Prehospital trials of magnesium sulfate are demonstrating the feasibility of delivering potentially brain-protective agents in the first minutes after stroke onset. Subacute neurorestoration therapies enhance neuroplasticity and brain reorganization after stroke. The greatest clinical experience with agents that can potentiate brain repair has been gained with choline precursors. Therapies that target the brain in patients with stroke will increasingly complement and enhance traditional vasotherapeutics.
Saver
Jeffrey L
JL
UCLA Stroke Center and Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA. jsaver@ucla.edu
D000818:Animals; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome
D018696:Neuroprotective Agents